Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT06381180

Warrior CARE: Cannabis Behavioral Health

This study is a randomized, controlled clinical trial to examine the therapeutic potential of cannabinoids for treating veterans with PTSD and suicidal ideation.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

19 year–69 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1 / Phase 2

Primary location

Wayne State University

Detroit, Michigan, 48201, United States

Location contact

Nareen Sadik, B.S.

CONTACT

About this study

In this clinical trial, we will recruit veterans with PTSD who report using cannabis or have interest in trying cannabis for symptom relief. Veterans will be randomized into one of four different groups: THC (∆9-tetrahydrocannabinol), CBD (cannabidiol), THC+CBD, and Placebo, and undergo a 12-week treatment phase where they will be asked to smoke their assigned cannabis dose every day for 12 weeks. Participants will complete weekly questionnaires regarding their mood, behavior and drug consumption. Furthermore, there is a laboratory component that will assess cognition, fear conditioning, and other PTSD-related measures.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • a healthy veteran who has served in a branch of the US armed forces
  • report using cannabis within the past year
  • currently meet DSM-5 criteria for PTSD and a score of 25 or greater on the CAPS-5 (the anchor, or index, trauma does not have to be related to military service)
  • between the ages of 19-69 years old
  • not seeking treatment for Cannabis Use Disorder
  • stable (i.e., under the care of a physician or therapist and not experiencing acute symptoms) on psychotropic medications and/or psychotherapy before the study begins (participants can be in treatment for PTSD)
  • agree to adhere to study procedures

Exclusion criteria

  • pregnant, lactating, or heterosexually active women and not using medically approved birth control
  • current or past bipolar or psychotic disorder as determined using the SCID-5
  • at immediate high risk for suicide based on the C-SSRS
  • current SUD other than Nicotine Use Disorder and Alcohol Use Disorder (mild or moderate)
  • allergies and/or other contradictions for using cannabis
  • any clinically significant medical problems
  • systolic/diastolic BP >140/90 mmHg or systolic BP <95 mmHg
  • elevated liver function tests
  • exhibit cognitive impairment (<80 IQ)
  • enrolled in another clinical trial or have received any drug as part of a research study within 30 days of dosing
  • used a prescription medication (with the exception of birth control) within 14 days of study entry that in the opinion of the medically responsible investigator will interfere with the safety of the participant or the study results
  • unable to provide informed consent

Treatment and study plan

tetrahydrocannabinol

Drug

Plant cannabis that will be smoked

Other names: THC

Cannabidiol

Drug

Plant cannabidiol that will be smoked

Other names: CBD

Placebo

Drug

Plant will be smoked.

Primary outcomes

  1. Assessing change in PTSD diagnosis and its symptom severity from pre-treatment to post-treatment using the CAPS-5 assessment.

    Time frame: Administered at a pre-treatment visit (at the initial screening visit); and at the four post-treatment visits (one week post-treatment and 3-, 6-, and 9-months post-treatment visits).

    PTSD diagnosis will be assessed using the Clinician-Administered PTSD Scale (CAPS-5) for DSM-5 Total Severity Score, a well-validated, semi-structured clinician interview that determines the presence and severity of PTSD symptoms and diagnosis consistent with the DSM-5 and allows for assessing changes in symptom severity over time.

  2. Assessing change in PTSD diagnosis and its symptom severity throughout the study using the PCL-5 assessment

    Time frame: Administered at every study visit: both pre-treatment visits (the initial screening and baseline visit); during the 12-week treatment phase (all twelve weekly visits); and the four post-treatment visits (one week post-treatment and 3-, 6-, and 9-months

    The PCL-5 is a 20-item self-report measure that assesses DSM-5 symptoms of PTSD. The PCL-5 is used to monitor symptom change during and after treatment, screen individuals for PTSD, and make a provisional PTSD diagnosis. This assessment will also be used as a safety measure at all visits by assessing PTSD symptom severity.

  3. Assessing Suicidality over time using the C-SSRS assessment.

    Time frame: Administered at a pre-treatment visit (at the initial screening visit); and at the four post-treatment visits (one week post-treatment and 3-, 6-, and 9-months post-treatment visits).

    The Columbia Suicide Severity Rating Scale (C-SSRS) is a clinician-administered interview assessing suicidal thoughts and behaviors over time. A baseline form is used to assess lifetime suicidal ideation, intensity, and behavior, and can be compared to current suicidal ideation and intensity assessed over the clinical trial.

  4. Assessing Suicidality throughout the study using the SBQ-R assessment.

    Time frame: Administered at every study visit: both pre-treatment visits (the initial screening and baseline visit); during the 12-week treatment phase (all twelve weekly visits); and the four post-treatment visits (one week post-treatment and 3-, 6-, and 9-months

    The Suicide Behavior Questionnaire-Revised (SBQ-R) is a brief (4-item), self-administered questionnaire that taps into four dimensions of suicidality (lifetime ideation/attempt, frequency of recent ideation, risk of suicide attempt and self-reported likelihood of future suicidal behavior). This assessment will also be used as a safety measure at all visits by assessing suicidality.

  5. Assessing mood and anxiety symptoms throughout the study using the BDI-II and STAI-Y Questionnaires.

    Time frame: Administered at every study visit: both pre-treatment visits (the initial screening and baseline visit); during the 12-week treatment phase (all twelve weekly visits); and the four post-treatment visits (one week post-treatment and 3-, 6-, and 9-months

    The Beck Depression Inventory-II (BDI-II) is a self-report depression checklist which assesses neurovegetative depressive symptoms. One item asks specifically about suicidal thoughts and will also be checked at every study visit as a safety measure. The State Trait Anxiety Inventory-Form Y (STAI-Y) is a 40-item questionnaire with two scales assessing state and trait anxiety (somatic and cognitive symptoms).

Secondary outcomes

  1. Assess emotional state pre- and post-treatment using the PANAS questionnaire.

    Time frame: Administered at a pre-treatment visit (at the baseline visit); and at the first post-treatment visit (one week post-treatment).

    The Positive and Negative Affect Schedule (PANAS) is a 20-item self-report questionnaire, widely used measure of emotional state, which has excellent psychometric properties.

  2. Assess feelings of loneliness pre- and post-treatment using UCLA's 3-ILS assessment.

    Time frame: Administered at a pre-treatment visit (at the initial screening visit); and at the first post-treatment visit (one week post-treatment).

    The UCLA Three-Item Loneliness Scale (3-ILS) assesses social isolation and feelings of loneliness.

  3. Assess dissociative symptoms pre- and post-treatment using the MDI and DSS assessments.

    Time frame: Administered at a pre-treatment visit (at the baseline visit); and at the four post-treatment visits (one week post-treatment, and 3-, 6-, and 9-months post-treatment).

    The Multiscale Dissociation Inventory (MDI) is a self-report questionnaire of dissociative symptomatology over the past month. The Dissociation Tension Scale (DSS) is a self-report measure of dissociative symptoms sensitive to weekly changes.

  4. Assess drug effects, liking, and symptoms after cannabis administration using the SCERF and SES visual analog scales.

    Time frame: Administered after cannabis administration; therefore, administered at the baseline visit and electronically during the 12-week treatment phase (at all twelve weekly visits).

    The Subjective Cannabis Effects Rating Form (SCERF) will ask participants to complete a Visual Analog Scale (VAS) of "good drug effect," "bad drug effect," "strength of drug effect," liking," "sedated," and "desire to take again" and indicate whether they thought they received active drug or placebo. The Subjective Effects Scale (SES) VAS is a 33-item scale which includes the phrase "I feel…" followed by adjectives describing a mood (e.g., "anxious", "friendly," "down," etc.), a drug effect (e.g., "high," "stimulated", "a good drug effect") or a physical symptom (e.g., "hungry," "tired," "restless").

  5. Assess demographics using a self-report assessment

    Time frame: Administered once at a pre-treatment visit, specifically at the initial screening visit.

    Participants will be asked to complete a personal history form to assess age, gender, sex, gender identity, marital status, race/ethnicity, education, employment status, and annual income.

  6. Assess toxicant exposure commonly experienced during war using the KGWIC and BPE assessments.

    Time frame: Administered once at a pre-treatment visit, specifically at the baseline visit.

    The Kansas Gulf War Illness Criteria (KGWIC) and the Burn Pit Exposure (BPE) are self-report questionnaires that contain items on toxicants commonly experienced as well as burn pit exposure during war.

  7. Assess smoking habits and history using the FTND assessment

    Time frame: Administered once at a pre-treatment visit, specifically at the baseline visit.

    Subjects who smoke cigarettes will also complete the Fagerstrom Test for Nicotine Dependence (FTND) survey to assess smoking history and habits.

  8. Assess general health and history pre- and post-treatment using the SF-36 assessment.

    Time frame: Administered at a pre-treatment visit (the baseline visit); and at the four post-treatment visits (one week post-treatment and 3-, 6-, and 9-months post-treatment visits).

    The Short Form 36 (SF-36) is a brief measure of overall self-reported health that is associated with other objective health measures. Scores will be examined to assess change in general health outcomes over time.

  9. Assess healthcare utilization throughout the study.

    Time frame: Administered at both pre-treatment visits (the initial screening and baseline visit); and at two post-treatment visits (one week post-treatment and 3-months post-treatment visits).

    The Healthcare Utilization (HU) survey will also assess the number of times participants utilize emergency room, urgent care, specialist, and general practitioner services.

  10. Assess pain pre- and post-treatment using the BPI assessment.

    Time frame: Administered at a pre-treatment visit (the baseline visit); and at the four post-treatment visits (one week post-treatment and 3-, 6-, and 9-months post-treatment visits).

    The Brief Pain Inventory (BPI) asks participants to identify areas on their body causing pain and rate the severity.

  11. Assess sleepiness pre- and post-treatment using the ESS questionnaire.

    Time frame: Administered at a pre-treatment visit (the baseline visit); and at the four post-treatment visits (one week post-treatment and 3-, 6-, and 9-months post-treatment visits).

    The Epworth Sleepiness Scale (ESS) is a self-report questionnaire that will be used to assess daytime sleepiness, which is indicative of sleep problems.

  12. Assess overall quality of life pre- and post-treatment using the QOL questionnaire.

    Time frame: Administered at a pre-treatment visit (the baseline visit); and at the four post-treatment visits (one week post-treatment and 3-, 6-, and 9-months post-treatment visits).

    The Quality of Life (QOL) inventory assesses satisfaction in 17 life areas (work, health, recreation, goals, etc.) and will be used to assess the quality of life changes.

  13. Assess substance use throughout the study using the TLFB assessment.

    Time frame: Administered at every study visit: both pre-treatment visits (the initial screening and baseline visit); during the 12-week treatment phase (all twelve weekly visits); and the four post-treatment visits (one week post-treatment and 3-, 6-, and 9-months

    The Timeline Follow-Back (TLFB) will be used to record the time of cannabis use and route of administration as well as any alcohol and other drug use.

  14. Assess neurocognitive and executive function pre- and post-treatment using the WCST, WMS, CVLT, HMDD, WCS, IGT tasks

    Time frame: Administered at a pre-treatment visit (the baseline visit); and at the four post-treatment visits (one week post-treatment and 3-, 6-, and 9-months post-treatment visits).

    Working Memory will be assessed using the Wechsler Memory Scale (WMS) and the California Verbal Learning Test (CVLT). The Wisconsin Card Sort Task (WCST) assesses abstraction and the ability to shift or maintain cognitive set. The Hypothetical Monetary Delay Discounting (HMDD) and the Iowa Gambling Task (IGT) measure decision-making. Lastly, the Word Color Stroop (WCS) task assesses selective attention capacity and skills.

  15. Assess physiological measures throughout the study as a safety check

    Time frame: Administered at every study visit: both pre-treatment visits (the initial screening and baseline visit); during the 12-week treatment phase (all twelve weekly visits); and the four post-treatment visits (one week post-treatment and 3-, 6-, and 9-months

    Physiological measures include blood pressure, heart rate, oxygen saturation, and skin temperature checks at all study visits

  16. Assess biological samples for genetic markers associated with the endocannabinoid system and other biomarkers (e.g., cortisol) and measure THC and CBD.

    Time frame: Biological samples may be collected at a pre-treatment (at the baseline visit); during the 12-week treatment phase; and at the four post-treatment visits (one week post-treatment and 3-, 6-, and 9-months post-treatment visits)

    Biological measures include collection of urine, saliva, and blood. Saliva will be used to measure biomarkers like cortisol and test for endocannabinoid levels. Urine will be used to measure THC and CBD and their metabolites. Blood plasma will be used to measure plasma concentrations of endocannabinoids, cannabinoids, and PUFA metabolites.

Study contacts

Contact information is provided by the study sponsor or research team.

Leslie Lundahl, PhD

CONTACT

[email protected]

3139931374

Paula Qefaliaj, B.S.

CONTACT

[email protected]

2487168321

Sponsors and collaborators

Lead sponsor

Wayne State University

Other

Registry information

Official study title

Wayne Warrior CAnnabis Research and Education: Cannabis and Behavioral Health

Acronym: CBH

Important dates

Study start
2025
Primary completion
2030
Study completion
2030
First posted
Apr 24, 2024
Registry last updated
Sep 29, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.